Latest Administration News

Finexia Financial Group has ended talks on a major disposal deal and is managing loan defaults with fresh collateral, while expanding its childcare lending strategy.

Nyrada’s Phase I clinical trial for Xolatryp™ concludes with positive safety and pharmacokinetic results, paving the way for a Phase IIa study in acute myocardial infarction patients.

Nanosonics has secured FDA clearance for its next-generation trophon3 device and trophon2 Plus software upgrade, setting the stage for significant growth in the US medical disinfection market.

Nutritional Growth Solutions revises its Q2 FY25 financials, confirming stable revenue and detailing expanded distribution into CVS and Walmart. The company is actively raising capital to support growth and improve liquidity.

ChemX Materials Limited has explained the delayed filing of director interest notices, attributing it to transitional challenges during its recent recapitalisation and governance overhaul.

Immutep has received encouraging feedback from the FDA on its immunotherapy eftilagimod alfa combined with KEYTRUDA for patients with low PD-L1 expression in head and neck cancer, opening potential accelerated approval pathways.

Coventry Group’s FY25 results reveal a sharp EBITDA decline amid ERP disruptions and soft markets, prompting a major cost reduction drive for FY26.

Macro Metals Limited has successfully raised A$2 million through a share placement, positioning itself to accelerate exploration and expand its mining services operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.

Universal Biosensors reported a 44% increase in net loss to A$10.45 million for H1 2025, alongside an 11% revenue decline, raising serious going concern doubts. The company is pursuing an A$8.5 million senior secured loan and equity raise to sustain operations.